profit from every $100 of sales.
$0$100
Trinity Biotech
$5.88+1.03% today
-78.2% in 1 year
1-year low $5.341-year high $38.40
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Trinity Biotech sold, what it kept, and what it did with the cash.
Sales went from $62.5 million in 2022 to $43.8 million in 2025, with -$37.4 million of profit last year.
SalesProfit
Trinity Biotech vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Trinity Biotech | No profit yet | ||
 Illumina | 37.3× · Expensive | ||
 Labcorp Holdings | 34.5× · Expensive | ||
 Quest Diagnostics | 28.8× · Fair price | ||
 Guardant Health | No profit yet |
AI analysis
An AI analyst reads Trinity Biotech's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 63 | 57 | 62 | 44 | |
| 17 | 19 | 21 | 17 | |
| -14 | -16 | -14 | -11 | |
| -30 | -25 | -17 | -21 | |
| -41 | -24 | -32 | -37 | |
| -6.08 | -3.20 | -1.77 | – | |
| 27.6% | 34.2% | 34.8% | 38.6% | |
| -21.6% | -28.1% | -22.3% | -26.1% | |
| -65.6% | -42.3% | -51.6% | -85.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 92 | 59 | 103 | 105 |
| Cash | 7 | 4 | 5 | 5 |
| Total debt | 72 | 67 | 101 | 138 |
| Total liabilities | 94 | 83 | 138 | 177 |
| -2 | -24 | -35 | -72 | |
| 7 | 9 | 18 | – | |
| -36.4% | -48.7% | -22.6% | -28.8% | |
| 1,884.6% | 100.3% | 90.4% | 51.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -1 | -12 | -4 | -6 | |
| 6 | 3 | 10 | 6 | |
| -7 | -14 | -14 | -12 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| – | – | – | – | |
| 2 | 2 | 1 | 0 |
Valuation
- –
- –
- –
- -0.2×
- 0.1×
- –
- –
- -254.2%
- -781.7%
- 0.0%
Profitability
- 38.6%
- -26.1%
- -85.4%
- -25.3%
- -15.1%
- -43.6%
- 68.1%
- -35.6%
- 31.2%
- 8.3%
Growth
- −11.2%
- –
- +55.5%
- –
- +45.2%
Financial health
- –
- -1.92
- 131.2%
- -0.5×
- 0.25
- 0.12
- 0.42
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 24%of 947
Bottom 11%of 872
Bottom 7%of 866
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | -0.90 | -0.32 | −181.3% |
| Dec 23, 2025 | -0.32 | -0.51 | +37.3% |
| May 15, 2025 | -1.02 | -0.30 | −240.0% |
| Jan 29, 2025 | -0.06 | -0.54 | +88.9% |
| Nov 15, 2024 | -0.43 | -0.54 | +20.4% |
| Aug 14, 2024 | -0.71 | -0.67 | −6.0% |
| Apr 4, 2024 | -0.68 | -3.50 | +80.6% |
| Jan 31, 2024 | -0.72 | -0.70 | −2.9% |
News
Trinity Capital Inc. Q3 2026 Earnings Call SummaryYahoo Finance · Nov 4, 2026Trinity Capital Q3 2026 Earnings PreviewSeeking Alpha · Nov 3, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
0No pass
Philip Fisher
23No pass
Peter Lynch
0No pass
Joel Greenblatt
0No pass
Charlie Munger
9No pass
Terry Smith
7No pass
Questions about Trinity Biotech
Is Trinity Biotech a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Trinity Biotech AI analysis
What does Trinity Biotech do?
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. It is in Medical - Diagnostics & Research.
Does Trinity Biotech pay a dividend?
No. Trinity Biotech does not pay a dividend at the moment.
Is Trinity Biotech stock halal?
No. Trinity Biotech does not pass our halal screen: its debt is 2,916% of its market value, at or above the 33% limit. How we check
How has Trinity Biotech stock done over the past year?
Down 78.2% over the past twelve months, to $5.88. It traded between $5.34 and $38.40 and is 84.7% below its high.
Who are Trinity Biotech's competitors?
The largest listed companies in the same industry are Illumina, Labcorp Holdings, Quest Diagnostics and Guardant Health. The peers table on this page compares their profit, growth and price with Trinity Biotech's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.